Veracyte shares surge 10.74% after-hours after reporting 14% revenue growth and raising 2025 guidance.

Veracyte surged 10.74% in after-hours trading following the release of its Q3 2025 financial results, which showed a 14% year-over-year increase in total revenue to $131.9 million and a 17% rise in testing revenue to $127.8 million. The company raised full-year revenue guidance to $506 million–$510 million (14% growth) and adjusted EBITDA guidance to over 25% of revenue, reflecting strong demand for its Decipher and Afirma tests. Management highlighted operational efficiency, margin expansion, and upcoming product launches like TrueMRD and Prosigna LDT as catalysts for sustained growth. The results exceeded expectations, with testing revenue growth outpacing prior guidance, directly driving the post-earnings rally.